Home > Publications database > Ethnic differences in metabolic syndrome in high-income countries: A systematic review and meta-analysis. > print

001     289367
005     20241121140341.0
024 7 _ |a 10.1007/s11154-024-09879-9
|2 doi
024 7 _ |a pmid:38598068
|2 pmid
024 7 _ |a 1389-9155
|2 ISSN
024 7 _ |a 1573-2606
|2 ISSN
037 _ _ |a DKFZ-2024-00757
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Adjei, Nicholas Kofi
|b 0
245 _ _ |a Ethnic differences in metabolic syndrome in high-income countries: A systematic review and meta-analysis.
260 _ _ |a Dordrecht [u.a.]
|c 2024
|b Springer Science + Business Media B.V
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1722606956_3118
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2024 Aug;25(4):727-750
520 _ _ |a This review aimed to systematically quantify the differences in Metabolic Syndrome (MetS) prevalence across various ethnic groups in high-income countries by sex, and to evaluate the overall prevalence trends from 1996 to 2022. We conducted a systematic literature review using MEDLINE, Web of Science Core Collection, CINAHL, and the Cochrane Library, focusing on studies about MetS prevalence among ethnic groups in high-income countries. We pooled 23 studies that used NCEP-ATP III criteria and included 147,756 healthy participants aged 18 and above. We calculated pooled prevalence estimates and 95% confidence intervals (CI) using both fixed-effect and random-effect intercept logistic regression models. Data were analysed for 3 periods: 1996-2005, 2006-2009, and 2010-2021. The pooled prevalence of MetS in high-income countries, based on the NCEP-ATP III criteria, was 27.4% over the studied period, showing an increase from 24.2% in 1996-2005 to 31.9% in 2010-2021, with men and women having similar rates. When stratified by ethnicity and sex, ethnic minority women experienced the highest prevalence at 31.7%, while ethnic majority women had the lowest at 22.7%. Notably, MetS was more prevalent in ethnic minority women than men. Among ethnic minorities, women had a higher prevalence of MetS than men, and the difference was highest in Asians (about 15 percentage points). Among women, the prevalence of MetS was highest in Asians (41.2%) and lowest in Blacks/Africans (26.7%). Among men, it was highest in indigenous minority groups (34.3%) and lowest among in Blacks/Africans (19.8%). MetS is increasing at an alarming rate in high-income countries, particularly among ethnic minority women. The burden of MetS could be effectively reduced by tailoring interventions according to ethnic variations and risk profiles.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Burden
|2 Other
650 _ 7 |a Ethnicity
|2 Other
650 _ 7 |a High-income Countries
|2 Other
650 _ 7 |a Meta-analysis
|2 Other
650 _ 7 |a Metabolic syndrome
|2 Other
650 _ 7 |a Prevalence
|2 Other
700 1 _ |a Samkange-Zeeb, Florence
|b 1
700 1 _ |a Boakye, Daniel
|b 2
700 1 _ |a Saleem, Maham
|b 3
700 1 _ |a Christianson, Lara
|b 4
700 1 _ |a Kebede, Mihiretu M
|0 P:(DE-He78)547386e1dd3330f9f40321e89ec05354
|b 5
|u dkfz
700 1 _ |a Heise, Thomas L
|b 6
700 1 _ |a Brand, Tilman
|b 7
700 1 _ |a Esan, Oluwaseun B
|b 8
700 1 _ |a Taylor-Robinson, David C
|b 9
700 1 _ |a Agyemang, Charles
|b 10
700 1 _ |a Zeeb, Hajo
|b 11
773 _ _ |a 10.1007/s11154-024-09879-9
|0 PERI:(DE-600)2018673-3
|n 4
|p 727-750
|t Reviews in endocrine & metabolic disorders
|v 25
|y 2024
|x 1389-9155
856 4 _ |u https://inrepo02.dkfz.de/record/289367/files/s11154-024-09879-9.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/289367/files/s11154-024-09879-9.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:289367
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)547386e1dd3330f9f40321e89ec05354
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-08-23
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-08-23
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-08-23
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b REV ENDOCR METAB DIS : 2022
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-23
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-23
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b REV ENDOCR METAB DIS : 2022
|d 2023-08-23
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21